Deep Science Ventures

Deep Science Ventures

Science-driven venture creation across sectors

Overview

Deep Science Ventures builds new companies by turning scientific knowledge into startup ventures. It combines scientist-founders with existing expertise to create high-impact businesses in Pharmaceuticals, Climate, Agriculture, and Computation. The process centers on a first-principles, evidence-based approach and close partnerships with top institutions to translate research into real-world solutions. Unlike typical investors or incubators, it acts as a venture creator that co-develops ideas, forms teams, and guides the whole company-building journey from lab concepts to market-ready ventures. The goal is to enable breakthroughs that help humanity and the planet thrive by addressing major challenges across its four sectors.

About Deep Science Ventures

Simplify's Rating
Why Deep Science Ventures is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Consulting

Venture Capital

Company Size

N/A

Company Stage

N/A

Total Funding

$34.3M

Headquarters

London, United Kingdom

Founded

2016

Get referred to Deep Science Ventures

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 MDC partnership targets brain-entry technologies and pre-seed spinouts for CNS therapeutics.
  • March 2026 Renaissance Philanthropy collaboration expands CERL, creating more climate and agriculture venture opportunities.
  • January 2026 reports show Flow Engineering raised $23 million Series A after DSV involvement.

What critics are saying

  • DSV’s model depends on partner-funded venture creation; one sponsor pullback freezes pipelines quickly.
  • No evidence of flagship exits beyond one acquisition; portfolio still lacks repeated venture-scale validation.
  • Brain-delivery, crop-resilience, and fibrosis programs each need long regulatory timelines before revenue.

What makes Deep Science Ventures unique

  • DSV builds companies from pre-scoped science, not random founder ideas, across four sectors.
  • By June 2026, DSV’s Venture Science Doctorate reached 40 lab partners globally.
  • DSV claims 58 companies launched, 12 in development, and $220 million funding attracted.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$34.3M

Above

Industry Average

Funded Over

0 Rounds

Benefits

Remote Work Options

Flexible Work Hours

Company Equity

Company News

EU-Startups
Jun 19th, 2026
Houdini Bio emerges from stealth with €1.7 million to tackle DNA silencing in gene therapies | EU-Startups

British BioTech startup Houdini Bio has exited out of stealth today with approximately €1.7 million (£1.5 million) in pre-Seed funding in order to

Tech Funding News
Jun 19th, 2026
Cambridge spinout Houdini Bio raises $1.9M to make gene therapies last longer

Houdini Bio has raised approximately £1.5 million in grants and pre-seed funding led by SCVC, the venture arm of Science Creates. Cambridge Enterprise VC and Deep Science Ventures also participated in the oversubscribed round. Founded in 2025, the Cambridge spinout has developed software that redesigns therapeutic DNA to prevent the body's HUSH protein complex from silencing it. The company claims its approach can increase gene expression more than tenfold compared to current methods, addressing a critical durability problem in gene and cell therapies. Chief executive Jonathan Cohen-Gold discovered the molecular workaround during his PhD at Cambridge. The startup will use the funding to expand its team and establish co-development partnerships with pharmaceutical companies. The global gene therapy market is projected to grow from $10.04 billion in 2026 to $25.89 billion by 2031.

Attention Worlds
Jun 8th, 2026
Ramaiah Academy Foundation collaborates with Dassault Systemes to accelerate Deep Science translation in India.

Ramaiah Academy Foundation collaborates with Dassault Systemes to accelerate Deep Science translation in India. Desk News Super Admin Jun 8, 2026 - 7:00 PM 0 0 "Ramaiah Academy Foundation collaborates with Dassault Systemes to accelerate Deep Science translation in India" Read more on attentionworlds.com 8 Jun 2026 The Ramaiah Academy Foundation (RAF) and Dassault Systemes today announced their collaboration aimed at bridging the critical gap between academic research and commercial-scale manufacturing. Central to this collaboration is the establishment of a Deep Science Translational Innovation Complex in Bengaluru, designed to accelerate productization in high-impact sectors including Aerospace & Defense, Healthcare & MedTech, Automotive, and Semiconductors. MoU exchange between Venkatesh Valluri, Vice Chairman, Ramaiah Academy Foundation, and Deepak N.G., Managing Director-India, Dassault Systemes This collaboration represents a first-of-its-kind model in the region, transitioning beyond a traditional academic arrangement into a fully integrated, go-to-market commercial partnership. It seamlessly leverages Dassault Systemes' globally recognized 3DEXPERIENCE platform alongside Ramaiah's deep science expertise and advanced prototyping infrastructure. This synergistic relation between RAF and Dassault Systemes aims to enhance the value for companies focused on enhancing their conceptual research & innovation; skill development of their engineers for newer projects; and acquiring newer talent. "This collaboration represents a paradigm shift in how academia and industry collaborate in India. We are moving beyond transactional skill development into a technology l translation engine," said Venkatesh Valluri, Vice Chairman, Ramaiah Academy Foundation. "Through the Deep Science translation complex, we are providing an end-to-end value chain, from problem definition and virtual twin simulation to physical lab-scale manufacturing," Valluri continued. "Our joint vision is to foster national-level 'projects' that embody the true spirit of Make-in-India, equipping both our industrial partners and our engineering talent with the world's most advanced technological tools." "At Dassault Systemes, we believe that shaping the future of industrial innovation starts with empowering the next generation of engineers and thinkers in the virtual world," said Deepak NG, Managing Director, India, Dassault Systemes. Our collaboration with the Ramaiah Academy Foundation reflects a shared commitment to bridging the gap between academia and industry through platform-driven learning. We aim to foster a culture of sustainable innovation and advanced engineering excellence that will drive India's high-tech and manufacturing ecosystems forward," he stated further. The Deep Science translational facility, currently undergoing advanced modifications on the Ramaiah campus in Bengaluru, will house state-of-the-art technical teaching centers, collaborative design spaces, and lab-scale manufacturing zones. About Ramaiah Academy Foundation The Ramaiah Academy Foundation (RAF), a Section 8 not-for-profit company, is a distinguished institution within the Gokula Education Foundation (Medical) ecosystem, carrying forward the legacy of excellence established by the renowned Ramaiah Group. Committed to fostering innovation, advancing applied sciences, and nurturing future-ready talent, the Foundation serves as a catalyst for transformative education, translational research, and industry collaboration. Founded with a vision to bridge the gap between academic discovery and real-world application, Ramaiah Academy Foundation focuses on creating impactful pathways that connect research, technology, entrepreneurship, and industrial growth. The Foundation actively promotes interdisciplinary learning, deep technology development, and innovation-led ecosystems that address emerging global challenges while contributing to India's scientific and economic progress. At the heart of its vision is the development of a world-class Translational Innovation Complex, a pioneering initiative designed to accelerate the journey of scientific discoveries from laboratories to large-scale commercial applications. The Complex will function as a robust commercial and innovation engine, addressing one of the most critical challenges in the research ecosystem - the Technology Readiness Level (TRL) gap. By enabling the seamless transition of technologies from proof-of-concept and prototype stages to scalable industrial manufacturing, the Foundation aims to create a sustainable bridge between academia, research institutions, startups, industry partners, and investors. The Translational Innovation Complex will provide an integrated platform for advanced research, product development, prototyping, testing, validation, and commercialization. It will foster collaboration among scientists, engineers, entrepreneurs, and industry leaders, creating an environment where breakthrough ideas can be transformed into market-ready solutions. Through this ecosystem, the Foundation seeks to accelerate innovation across strategic sectors including advanced materials, life sciences, healthcare technologies, artificial intelligence, robotics, semiconductor technologies, sustainable energy, and other deep-tech domains. Ramaiah Academy Foundation is also committed to developing industry-ready talent through specialized education, skill development, and experiential learning initiatives. By combining academic rigor with practical application, the Foundation equips learners with the knowledge, skills, and mindset required to thrive in an increasingly technology-driven world. Its programs are designed in close collaboration with industry stakeholders, ensuring alignment with evolving workforce requirements and global best practices. Guided by the values of excellence, integrity, innovation, and societal impact, the Foundation strives to create meaningful opportunities for researchers, students, entrepreneurs, and industry partners. Through strategic collaborations with leading academic institutions, research organizations, government agencies, and global industry leaders, it aims to establish a vibrant innovation ecosystem that drives technological advancement and economic development. As India continues its journey toward becoming a global innovation powerhouse, Ramaiah Academy Foundation stands poised to play a pivotal role in shaping the future of research, technology commercialization, and talent development. By transforming ideas into impact and research into real-world solutions, the Foundation is creating a platform where innovation meets industry, knowledge meets opportunity, and vision translates into lasting societal progress. rss_feed Disclaimer Story published through syndicated feed. Publisher:: News Voir admin_panel_settings Disclaimer: This post is officially published by the Administrator. favorite Follow us for the latest updates:

Medicines Discovery Catapult
Jun 2nd, 2026
Deep Science Ventures and Medicines Discovery Catapult partner to accelerate next-generation brain treatments.

Deep Science Ventures and Medicines Discovery Catapult partner to accelerate next-generation brain treatments. New strategic collaboration aims to overcome long-standing barriers in brain-targeted drug discovery. 2 June 2026 Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain. One of medicine's greatest challenges is ensuring that treatments reach the precise area of the body where they are needed. While recent scientific breakthroughs have identified numerous targets for neurological conditions, the difficulty of effectively transporting these treatments across the blood-brain barrier and into the central nervous system (CNS) remains a primary challenge for global health. According to the World Health Organization's Global Status Report on Neurology, over 40% of the global population is living with CNS diseases, making them a leading global cause of ill health and disability. Developing new solutions could unlock access for rare neurological disorders and expand treatment to large or underserved patient populations, including those with diseases like Alzheimer's and Parkinson's and various brain cancers. Directly addressing critical gaps in healthcare means these innovations have the potential to improve patient outcomes while creating clinical and commercial opportunities for biotech and pharma companies. The first phase of the partnership will see an in-depth review of the current medicines landscape conducted to identify opportunities for innovation. This information will then be used to identify systemic gaps in brain-entry technologies. The long-term ambition is for novel approaches that meet the investment criteria of the partners to be spun out into new ventures focused on high-impact solutions and to provide them with pre-seed funding. A core part of DSV's approach involves building future founding teams to form new companies that will address challenges across multiple sectors. Future founders will work on opportunities that have been pre-scoped by DSV, de-risking the standard founder proposition. By combining DSV's unique venture-building model with MDC's drug discovery expertise and infrastructure, the partnership will develop new approaches to ensure life-changing medicines reach the brain. "The blood-brain barrier remains one of the most complex issues in modern medicine and with over 40% of the world's population facing neurological conditions, it's imperative that we find an optimal solution to this problem," said Adam Tomassi-Russell, Senior Director, Deep Science Ventures. "By pooling our venture-creation expertise with MDC's discovery capabilities, we can offer the right founders a frictionless environment in which to tackle the CNS delivery gap. If we can solve the 'how' of brain entry more effectively, we can unlock a new frontier of CNS therapeutics and address the huge unmet need in these diseases." Dr Nicola Heron, Chief Strategy Officer at Medicines Discovery Catapult, said: "At MDC, we are committed to transforming bold ideas into better treatments. This collaboration presents an opportunity to discover new technologies that could have a significant impact on patients and society. Through this partnership, we will strengthen the ecosystem for CNS innovation in the UK and beyond, enabling more medicines to reach patients faster." Find out more about how MDC's expertise can accelerate drug discovery and make every move count here.

Tech.eu
Mar 26th, 2026
DSV and Renaissance Philanthropy set out to rewire crop resilience innovation.

DSV and Renaissance Philanthropy set out to rewire crop resilience innovation. The partnership aims to create commercially viable deeptech companies that can respond to climate volatility faster than traditional genetic approaches. Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Renaissance Philanthropy, a nonprofit fueling a 21st-century renaissance by increasing the ambition of philanthropists, scientists, and innovators, today announce a venture-creation project designed for systemic intervention in crop resilience. The project is part of DSV and Renaissance Philanthropy's existing partnership to form the Climate Emergencies Resilience Lab (CERL). Moving beyond traditional genetic modification, the initiative establishes a high-ambition roadmap to address the economic threat of climate-induced crop failures by creating commercially viable, deep-tech spin-outs. By 2050, climate-driven agricultural collapse and malnutrition could cost the world $1.8 trillion and 887 million years of healthy human life. This is not a distant projection; recent droughts and heatwaves have already destroyed up to 50 per cent of harvests across California, Southeast Brazil, and the Horn of Africa, while pre-harvest sprouting alone costs more than $1 billion annually. However, the dominant approach- of engineering crops for permanent genetic resilience is reaching its limits. Hardwiring heat tolerance into a plant's DNA often results in a "yield penalty" in normal years, while novel traits can take 10+ years to reach the market. As climate extremes grow less predictable, these static, time-consuming solutions are becoming increasingly unviable for global food security. However, a convergence of technology breakthroughs means that it is becoming possible to tune resilience in alignment with climate risks. The DSV and Renaissance Philanthropy partnership has identified three high-growth technical pillars ready for venture creation and institutional backing: * Forecasted priming to enhance stress pathways and orchestrate developmental processes, combining short-term weather accuracy with biologicals such as RNA or peptides to tune crops in real time. * Environment-responsive protectants and field-robust symbiotic microbes, enabling stress tolerance to be outsourced and reliably activated under specific conditions. * Foundational breeding tools to rapidly expand the available palette of resilience traits, for example, by engineering wild relatives or donor plants to circumvent barriers including crossing, linkage drag and epistasis. The partners seek to identify and embed specialised talent to lead technical and commercial scoping. These individuals will define a specific market or environmental need and work backwards to build the necessary field-ready data packages. Unlike traditional models, this approach does not rely on an initial laboratory breakthrough or a chance discovery. By intentionally engineering the R&D, regulatory, and IP strategies toward a predetermined outcome, the initiative ensures that innovation is targeted where it can achieve the greatest global economic and nutritional impact. "We are mapping the white space where science meets commercial markets," said Dom Falcao, co-founding Director at Deep Science Ventures. "This is about creating a de-risked pathway that transforms plant science into investment-ready companies. We are providing the systematic architecture to turn primed resilience into a dominant market category." "Renaissance Philanthropy was built to advance entire fields," said Joshua Elliott, Chief Scientist at Renaissance Philanthropy. "By furthering our partnership with DSV, we are enabling visionary philanthropic capital to act as a bridge for innovations that are too complex for traditional early-stage funding but too critical to ignore. The next generation of agricultural tech must exist in the field, protecting livelihoods and preventing the social unrest caused by food insecurity. We look forward to partnering with collaborators, including scientists, funders and other experts, to realise our goals and encourage them to reach out to us."

Recently Posted Jobs

Sign up to get curated job recommendations

Deep Science Ventures is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →